NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 119 filers reported holding NURIX THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $186,730 | -17.1% | 23,757 | +5.3% | 0.00% | 0.0% |
| Q2 2023 | $225,304 | +13.3% | 22,553 | +0.7% | 0.00% | 0.0% |
| Q1 2023 | $198,868 | -17.5% | 22,395 | +2.0% | 0.00% | -50.0% |
| Q4 2022 | $241,000 | -16.0% | 21,949 | -0.4% | 0.00% | 0.0% |
| Q3 2022 | $287,000 | +9.1% | 22,028 | +6.1% | 0.00% | 0.0% |
| Q2 2022 | $263,000 | +20.6% | 20,752 | +33.5% | 0.00% | +100.0% |
| Q1 2022 | $218,000 | -54.8% | 15,550 | -6.6% | 0.00% | -50.0% |
| Q4 2021 | $482,000 | -6.2% | 16,644 | -2.9% | 0.00% | -33.3% |
| Q3 2021 | $514,000 | +10.3% | 17,142 | -2.3% | 0.00% | +50.0% |
| Q2 2021 | $466,000 | +7.4% | 17,550 | +25.8% | 0.00% | 0.0% |
| Q1 2021 | $434,000 | +94.6% | 13,953 | +106.0% | 0.00% | +100.0% |
| Q4 2020 | $223,000 | -3.9% | 6,772 | +2.0% | 0.00% | 0.0% |
| Q3 2020 | $232,000 | – | 6,641 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $18,210,601 | 1.88% |
| DAFNA Capital Management LLC | 556,695 | $5,561,383 | 1.52% |
| Deep Track Capital, LP | 2,997,830 | $29,948,322 | 1.39% |
| Redmile Group, LLC | 2,857,309 | $28,544,517 | 1.10% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,830,497 | 0.80% |
| Boxer Capital, LLC | 1,224,892 | $12,237 | 0.57% |
| AtonRa Partners | 30,142 | $301,119 | 0.47% |
| Affinity Asset Advisors, LLC | 100,000 | $999,000 | 0.35% |
| HARVARD MANAGEMENT CO INC | 314,762 | $3,144 | 0.31% |
| WASATCH ADVISORS LP | 3,869,775 | $38,659,052 | 0.23% |